Intelligence ยท Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors โ phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text โ searchable for business development and competitive intelligence.
-
NK510
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC
1 trial -
Neoadjuvant chemotherapy
Hospital Authority, Hong Kong
Squamous Cell Carcinoma of Oral Cavity
1 trial -
NeuroRegen scaffold with BMMCs or MSCs transplantation
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Spinal Cord Injury
1 trial -
Nicorette Extra Mint 2 mg Gum
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Tobacco Dependence
1 trial -
Nivolumab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Effect of Drug
1 trial -
OPB-51602
Hospital Authority, Hong Kong
Nasopharyngeal Carcinoma
1 trial -
Octreotide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Enterocutaneous Fistulas
1 trial -
Olfactory ensheathing cells
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Infarction, Middle Cerebral Artery
1 trial -
Olverembatinib, APG-2575, Dexamethasone
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lymphoblastic Leukemia, Acute, Childhood
1 trial -
Omega 3 fatty acid
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Male Infertility Due to Hypospermatogenesis
1 trial -
Oncolytic Virus SDJ001
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Malignant Tumor
1 trial -
Oxidized regenerated cellulose(ORC)
Hospital Authority, Hong Kong
Thyroidectomy
1 trial -
Oxycodone (OxyNormยฎ) Injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pain
1 trial -
Oxycodone Tamper Resistant
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chronic Pain
3 trials -
Oxytocin
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Oxytocin Effect on Memory Performance During Phase 1
1 trial -
Oxytocin lower does (24IU)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy Adult Male
1 trial -
Oxytocin lower dose (24IU)
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healhty
1 trial -
Oxytocin nasal spray
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Healthy
1 trial -
PEGylated recombinant human interferon alpha-2b injection
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Hepatitis B, Chronic
1 trial -
PRG-1801
Hospital Authority, Hong Kong
Immune Thrombocytopenia
1 trial -
PRG2302
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
Paclitaxel
Hospital Authority, Hong Kong
Ovarian Cancer
1 trial -
Pemetrexed
The First People's Hospital of Lianyungang
Leptomeningeal Metastases
1 trial -
Phase Ib of Cyclophosphamide, Pomalidomide, Dexamethasone and Daratumumab (CPD-DARA) in patients with relapsed/refractory multiple myeloma. (The CPD-DARA Study).
Ningbo Cancer Hospital
Relapsed/ refractory multiple myeloma
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1โ3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync โ verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources